← Back to Clinical Trials
Recruiting NCT07133139

NCT07133139 Treatment Validation for Myofascial Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07133139
Status Recruiting
Phase
Sponsor Ajay Wasan, MD, Msc
Condition Chronic Low-back Pain (cLBP)
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-10-06
Primary Completion 2027-08-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Dry NeedlingSham Dry NeedlingNUN Biomarker

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2025-10-06 with a primary completion date of 2027-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to see if a body test called the NUN biomarker can track changes in chronic low back pain after dry needling and predict who will feel better. This study is for adults with chronic low back pain from muscle pain (Myofacial Pain). The main questions are: * Does the biomarker drop when pain improves? * Can it predict who benefits most? * Do higher starting levels mean better results with real dry needling? Investigators will compare real and fake (sham) dry needling using ultrasound, muscle pressure tests, and pain reports before and after treatment.

Eligibility Criteria

Inclusion Criteria: * Ages 20-70; * Predominantly axial LBP (meeting NIH definition of cLBP with daily pain for at least 3 months) with a MP component as determined by the standardized examination for MP; * Average pain score of \> 3/10, with low back pain being the primary pain site; * CLBP meeting Quebec Task Force Classification System categories I-III (from axial pain only to pain radiating beyond the knee without neurological signs). Constant radicular pain associated with sensory loss is likely a confounder to dry needling treatment success; * NO HISTORY of receiving dry needling, to improve the effectiveness of the blind; * Demonstration of healthcare seeking at some point for LBP. Exclusion Criteria: * Back surgery within the past six months; * Active workers' compensation or litigation claims, since these patients are more likely to have exaggerated pain behavior; * New pain treatments within 2 weeks of enrollment; * Any clinically unstable systemic illness or condition that is judged to interfere with the trial; * Non-ambulatory status; * Not able to complete the questionnaire * Currently pregnant or have intentions to become pregnant during the study.

Contact & Investigator

Central Contact

Ajay Wasan, MD, MSc

✉ wasanad@upmc.edu

📞 412-665-8048

Principal Investigator

Kang Kim, PhD

PRINCIPAL INVESTIGATOR

University of Pittsburgh

Frequently Asked Questions

Who can join the NCT07133139 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 70 Years, studying Chronic Low-back Pain (cLBP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07133139 currently recruiting?

Yes, NCT07133139 is actively recruiting participants. Contact the research team at wasanad@upmc.edu for enrollment information.

Where is the NCT07133139 trial being conducted?

This trial is being conducted at Pittsburgh, United States.

Who is sponsoring the NCT07133139 clinical trial?

NCT07133139 is sponsored by Ajay Wasan, MD, Msc. The principal investigator is Kang Kim, PhD at University of Pittsburgh. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology